The medical technology company reported a notable insider sale in recent filings.

I recommend a buy rating for HeartFlow, Inc. due to its strong clinical workflow integration and exp

Heartflow Plaque Staging TM , the only staging tool based on total plaque volume * , is now included

Heartflow uses artificial intelligence to transform coronary imaging into actionable diagnostic data

Heartflow leverages AI-enabled software to dominate the non-invasive coronary diagnostic market, bac

Freedom Capital Markets analyst Gene Mannheimer initiates coverage on HeartFlow (NASDAQ:HTFL) wit

AI-powered diagnostics meet global oncology innovation as two medical disruptors post strong revenue

In the first quarter of 2026, Baron Discovery Fund declined 10.65% (Institutional Shares), trailing

HeartFlow delivers AI-powered, non-invasive cardiac diagnostics for hospitals and cardiology clinics

Heartflow NASDAQ: HTFL reported a sharply higher first-quarter revenue total and raised its full-yea

HeartFlow, Inc. (HTFL) Q1 2026 Earnings Call Transcript

SAN FRANCISCO, May 14, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the lead

Heartflow and Neptune Insurance deserve a closer look.

HeartFlow provides AI-driven tools for non-invasive heart diagnostics, serving hospitals and clinics

SAN FRANCISCO, April 23, 2026 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the le

Heartflow, Inc. (NASDAQ: HTFL - Get Free Report) has received a consensus rating of "Moderate Buy" f

Heartflow asserts that Cleerly infringed foundational patented technology central to the Heartflow P

Heartflow, Inc. (NASDAQ: HTFL - Get Free Report) insider Campbell Rogers sold 64,533 shares of the f

/PRNewswire/ -- USANewsGroup.com News Commentary - Heart disease is a quiet crisis that is draining

HeartFlow's chief medical officer exercised 67,017 options and sold 64,533 Common Stock shares on Ma

HeartFlow delivers AI-powered, non-invasive cardiac diagnostics to healthcare providers seeking adva